Organization · Venture Capital
Third Rock Ventures
Third Rock Ventures is a venture capital firm based in Boston and San Francisco, focusing on creating and building companies that translate scientific innovations into breakthrough medicines in the life sciences sector.
Overview
What Third Rock Ventures does
What Third Rock Ventures is
Third Rock Ventures is a venture capital firm based in Boston and San Francisco, focusing on creating and building companies that translate scientific innovations into breakthrough medicines in the life sciences sector.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2007
- Approximate age
- About 19 years
- Structured capabilities
- Funder
- Last reviewed
- February 28, 2026
Official channels
Find Third Rock Ventures elsewhere
Open the official website or a supported primary organization account.
Capability profile
Third Rock Ventures as a funder
Investment thesis
Build transformational life science companies at the intersection of science, strategy, business and medicine. Focus on biotechnology, medical devices, diagnostics, therapeutics, and digital health addressing unmet medical needs.
Focus narrative
Series A and B investments with $30-100M first checks. Focus on transformational life science companies in biotech, diagnostics, devices, therapeutics, and digital health. Emphasis on ultra-orphan and rare genetic disorders, cancer, cardiovascular disease, and neuropsychiatry.
Value beyond capital
Hands-on operational support spanning drug discovery, clinical strategy, business operations, and talent acquisition. Deep scientific expertise from PhD scientists and experienced biotech executives. Active involvement from company formation through commercialization.
Terms and economics
- Typical check
- $30,000,000–$100,000,000
- Sweet spot
- $55,600,000
Focus and fit
- Stages
- Series A · Series B
- Sectors
- Biotech · Diagnostics · Digital Health · Medical Devices
- Regions
- United States
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 72
- Investments in the last 12 months
- 4
- Last recorded investment
- December 2, 2025
Portfolio context
72 companies, 19 IPOs (Maze Therapeutics, Septerna, Blueprint Medicines, Foundation Medicine, Sage Therapeutics, Editas Medicine), 23 acquisitions. 18 market-approved products. Recent: Syremis Therapeutics ($165M Series A, Dec 2025), Azalea Therapeutics, Corner Therapeutics.
Common questions
What to know about Third Rock Ventures
Upseed classifies Third Rock Ventures under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
February 28, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.